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doses of clopidogrel were effective in presence of aspirin suggesting clopi- 
dogrel and aspirin may have synergistic effects in prevention of acute stsnt 
thrombosis. 
• Tielopidine Attenuates Post-~tent Implantation 
Thrombln Generation 
Luisa Gregodni, Jean Marco, Jean Fejadet, Bernard Cassagneau, 
Philippe Brunet, Yannie Gablache, Monique Bemies, Irene Bossi, P. 
Marmuccio Mannucel. Clinique Pasteur, Toulouse, France: Clinica Medics 
- -  Ospedale Maggiore, Universit~ di Milano, Italy 
Stent implantation (S) is a procedure that fractures ar~ ~blates the endothe- 
lium, consequently ectivates hemostasis. Ticlopidine (T) and Aspidn (ASP,) 
are thought o protect patients (pts) undergoing dilatation from thrembus for- 
mation. Being unknown the level of intracoronary thmmbin generation, in 35 
pts undergoing S implantation for a76 -~ 2% stenosis we measured thrombin 
antithrombin complexes (TAT) and the prothrombin fragment 1 + 2 (F1 + 2) in 
blood withdrawn from a peripheral vein (Bas Vein) and the proximal coronary 
artery (Ba~s Art). Measurements were repeated soon after and 10 m|n a~ter 
S + PTCA, collecting blood in the distal dilated vessel (Dist Art) through a 
0.018-inch intemel lumen probing catheter. All pts were pretreated with 250 
mg/d ASA, 500 mg/d T,/;-blockers, calcium-antagonists and nitrates. Dudng 
dilatation f50 U/Kg iv hepsrin (H) and 3 + 3 mg isosorbidedinitrate (ISDN) 
were ic iniected. Eighteen pts received <_ 24 h T and 17 pts >_ 72 h T. 17 pta 
had GT-Roubin and 18 had Pelmaz-Schatz stenVs (PaI-Sch) implantation. 
Results: 
+ PTCA 10 rnin 
Bas Vein B~s Art 0ist Art Dist A~t 
TAT R <24hT ng/ml . [10.84-3 . 1-154-4.3. [10.8:L-4 . 1.13.54-4.1 
TAT R _> 72 h T ng/ml ~ 3.04-0.2 L2.9..L.0. 2 L 3.6:L--0.6 L 2,9:L-0`2 
TAT P <24hT ng/ml 11.1:E2A]o 13.34-6 "]. 16.7:L-6 "]. 7.64-1.5]. 
TAT P >_72hT ng/ml 3.0±0.3 2,6:1:0.2 ~ 2,9:L-0.1 ~ 2.'/4-0.1 J 
F1 +2 P. <24hT nmoUL. [1.6:L0.1 . [2.94-0.5 . rl.g=EQ.4 . i2.4=E0.7 
F1 + 2 R >_ 72 h T nmol/L * 1,04-0.2 = 1.04-0.2 ~ 1,0¢-0.2 L 0,94-O.3 
F1 + 2 P _ 24 h T nmol/L 1.44-0.2 ] .  2.44-0.9 ] .  2.2:L-0,8 ] .  1.6:EOA "1" 
F1 + 2 P _> 72 h T nmot/L 0.94-0.1 = 0.84-0.1 = 0.8i-0.1 • 0.8:E0.1 J 
R - Roubin; P - Palmaz-Schatz; mean 4- Sem (Anova), *Significant contrast vs < 24 h T 
The intTa-precedure thmmbin generation did not increase vs normal con- 
trois venous values (TAT 2A1 :t: 1.4 ng/ml, F1 + 2 1.1 ± 0.3 nmol/L) after S 
+ PTCA in pts receiving ASA + >_ 72 h T + H. Ca antagonists, ISDN, ASA, H 
and <_ 24 h T did not completely attenuate thrombin generation. No significant 
differences in thrembin generation were found between pts In whom Roubln 
or Palmaz-Schatz stents were implanted. 
Conclusions:Thrombin generation following S + PTCA is reduced in pa- 
tients treated with combination of ASA and >_. 72 h Ticlopidine. The combined 
use of ASA, H and > 72 h T might 0ffectlvely protect Patients from thrembus 
formation. 
~ Thrombin and Act iv i ty In Patients Treated Fibrin 
With Enoxaparin, Tielopldlne and Aspirin Versus 
the Conventional Coumedin Regimen After 
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Umited data are available comparing the Impact of the various antithrembetic 
drug regimens on hsmostatio markers of thrombosis in the setting of intre- 
coronary stanting. A 120 patient multicanter tdal was organized to determ|ne 
which antlthrombetlc regimen was more effective tn reducing thrombosis. Pa- 
tients were randomized In a 2:1 f~hion to enoxaparln, ticicpldine, and aspirin 
(ETA) or to warfarin, hepadn, dextran, dipyridamole, and aspidn (WHDDA). 
B/oDd samples were obtained preprecedure (baseline) and 3 days post- 
procedure. The hematologic markers performed Ir¢tuded fibdnopapfJde A 
(FPA), thtombin.antithrombfn III complex (TAT), prothrombln fragment (F1.2), 
D-Direst (D-D), and platelet factor 4 (PF4). For quality assurance, a collected 
sample was defined as inadequate and excluded from analysis if the value 
of the FPA was > 8.0 pg/L Results for the first 40 patlen~ are summarize 
below and ~-,=~-asent the change Imm besellne to day 3 post-procedure. 
Values m expressed as mean ± standard error. 
FPA ~ TAT qg/ml F1.2 .g/we D-D qMfml PF4 IU/ml 
ETA -0.B24-0.64 -2,2*0.54 -0,24-0.07 -5.34-10.6 +1~.5.7.e 
Wt'lOE~l~ -0,814-0.53 -1.04-0,64 -0.(]2:1:0.05 +59.8±6.4 +18,5=E15.4 
~ :  An h~erlm ana~is su0gasts that the hematologic 
of thmmbin and tibdn generation are suppressed to a greater extent by a 
treatment strategy consisting of enoxaparin, ticlopidine, and aspirin. At the 
completion of the trial, a final analysis and correlation between these markers 
and clinical outcomes will be performed. 
9~4- - - -~  Platalet l ib/Il ia B lockade wi th  Integrel in: 
Atherectomy Patients 
Paul S. Teirstein, Stsven J. Yakubav, Mark C. Thor, Nancy Wildermann, 
Dean J. Kerelakas, Jeffrey J. Popma, Michael A. Lincoff, James E. Tcheng, 
Robert M, Califf, Ede J, Topoi. Scripps Clinic and Research Foundation, La 
Jells, CA 
The IMPACT-II trial compared placebo and high- and low-dose integrelin, a 
ptatetet lbfllta inhibitor, in patients undergoing intervantionat procedures. Of 
=;,010 pts randomized, 819 underwent either directional atherectomy (DCA; 
451,11.2°/=) or Rotablater atherectomy (ROTA; 380, 9.5%). Although not risk- 
adjusted for baseline lesion characteristics, the composite 30-day endpoint 
(death, MI, urge=it bypass, repeat angicplasty or stant) was higher in DCA 
than non-DCA pts (15% vs 10%, p-- 0.002) and in ROTA than non-ROTA pts 
(15% vs 10%, p = 0.001). 
Placebo Integre!in , P 
Low.Dose High-Dose -- , 
DCA p~ 
Composite ndpoint 16.1% 13.4% 15.2% 0.619 
M! 11.9% 12.2% 13.1% 0.816 
Urgent CABG 1.4% 0 <1% 0.213 
ROTA pts 
Composite rzdgeint 19.9°/= 12,5% 12,4% 0.059 
MI 14.5% 10.2% 10.7% 0,304 
Urgent CABG 7.6% 1.6% 2.5% 0.010 
Although not dsk-adjusted, in this large-scale, randomized trial composite 
ischemic events were 50% higher in DCA and ROTA pts. Integrelin markedly 
suppressed these events in ROTA pts and had a modest effect in DCA pts. 
~ ' ~  Local Del ivery o f  Tissue Pathway Factor Inhibitor 
(TFPI) Decreases Mural Thrombus Formation 
Induced by Bal loon Angioplasty 
Wang Zesheng, Daniel H~bert, Aaron V. Kaplan, Abla Crease),, Gerald 
R. Geluppi, Jules Y.T. Lain. Montreal Heart Institute, Montreal, Quebec, 
Canada 
Tissue factor is the most potent activator of blood coagulation, and is believed 
to have a critical function in hemostasis and thrombosis. Tissue factor may 
also be implicated in thrombus formation when the vessel wall is injured 
during balloon angioplasty, and may thus play an important role in abrupt 
closure and restenosis following engioplasty. 
Whether in vivo administration of a tissue factor pathway inhibitor (TFPI) 
locally at the site of artedal wall injury, could prevent platelet thrombus 
formation was studied in normal pigs that underwent carotid arterial injury by 
a balloon dilatation catheter (5 inflations at 6 arm pressure for 30 sec at 1 rain 
inteP~al), after which TFPI was dellversd Iocatly and (ntmmure, fly at the site 
of angicplasty Ihrough the distal micropores of a Localmed infusion sleeve. 
The left carotid was treated with 0.2 #g/kg of TFPI, while the right carotid 
was treated with vehicle solution. Autelogous st Cr-platelet (PLT) deposition 
was quantified at the site of deep arterial injury, and was reduced from 28.1 
:~ 5.9 x 1Oe/cm 2 on the control ert~ry (n = 7), to 14.5 ~- 4.3, p = 0.06 (n = 
10) on the TFPI treated side. Pmthmmbin time was not changed with TFPI 
administration. 
Thus, local administration of tissue factor pathway inhibitor via the Lo- 
calmed infusion sleeve is feasible, and is associated with a 48% decreased 
ptatelat hrembus formation at the site of deep arterial injury, suggesting that 
tissue factor may be implicated in the thrombotic response after be,con an- 
gioplasty. This may have important clinical implications in the prevention of 
abrupt closure and restenosis following PTCA. 
~ F.xpression o f  p53, bFGF and TGF~I In 
Atherectomy ~iopldes 
Peter Gonechlor, Hans Lehr ~, Berthoid HSfling. Mecrk:~ ~ n t  I, 
K/inlT(um Gresshadem; U..n/vers/ty of Munk:h; = Dept. Palhotogy, Unfve~, 
of Washington 
DL~u~on ot p53 was ar~ us~ a nx~o~onaJ a r~ ~g~.~ ~e 
e l~ of the amino a~d sequence I-4S in 48 t ~  (25 ,~=~oses) 
o ~  at ~rec~.~ comna~ a ~ .  The ~ 
ant~en K'HS7 (MIB 1), me ~ e  rasmants (=-stUn, desmln), m=rix 
comp~e~s coita0~ Vl and the beasmm~ memblm~ comlxx~n~ c~la. 
pan No MIB 1. bF3F and TGFn, were mtelyaed k 1 1 r ~  udng 
